抗新型冠状病毒药物与治疗浅谈

doi:10.12092/j.issn.1009-2501.2020.06.015

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (6): 716-720.doi: 10.12092/j.issn.1009-2501.2020.06.015

• 综述与讲座 • 上一篇

抗新型冠状病毒药物与治疗浅谈

郝玉奇¹, 肖遥¹, 王乾¹, 姜兴旭²

¹天佳吉瑞基因科技有限公司技术部,合肥 238000,安徽;
²信阳农林学院,信阳 464000,河南

收稿日期:2020-05-10 出版日期:2020-06-26 发布日期:2020-07-09
通讯作者: 王乾,男,博士,研究方向:遗传解读、胚胎干细胞、肿瘤干细胞的维持分化以及相应的分子机制研究。Tel: 18310957637 E-mail: wangq@tianjiagenomes.com
作者简介:郝玉奇,女,硕士,高级分子病理分析师,研究方向:肿瘤分子病理,二代测序数据分析。Tel:18788821953 E-mail:haoyq@tianjiagenomes.com

Therapeutic drugs and treatment of SARS-CoV-2

HAO Yuqi¹, XIAO Yao¹, WANG Qian¹, JIANG Xingxu²

¹ Tianjia Genomes Tech CO., LTD., Hefei 238000, Anhui, China;
² Xinyang Agriculture and Forestry College, Xinyang 464000, Henan, China

Received:2020-05-10 Online:2020-06-26 Published:2020-07-09

摘要/Abstract

摘要： 2019年12月,武汉发生了由新型冠状病毒(SARS-CoV-2)引起的新型肺炎,截至2020年3月8日全国已有8万余人感染。目前尚无针对SARS-CoV-2的药物。本文对目前上市及研发中的抗病毒药物,包括体外、动物及临床试验数据进行整理,为SARS-CoV-2的防治提供参考。

关键词: 新型冠状病毒, 新药研发, 研发思路, 临床试验

Abstract: Novel coronavirus pneumonia caused by the SARS-CoV-2 appeared in Wuhan, China in December 2019. The virus spread rapidly across the country and resulted in the infection of more than 80000 people by March 8,2020. This paper introduces the data of tested drugs in vitro, in animal and in clinical trials marketed and in research, in hoping of providing reference for the prevention and control of SARS-CoV-2.

Key words: SARS-CoV-2, research of new drug, research and development ideas, clinical trials

中图分类号:

R979.4

郝玉奇, 肖遥, 王乾, 姜兴旭. 抗新型冠状病毒药物与治疗浅谈[J]. 中国临床药理学与治疗学, 2020, 25(6): 716-720.

HAO Yuqi, XIAO Yao, WANG Qian, JIANG Xingxu. Therapeutic drugs and treatment of SARS-CoV-2[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 716-720.

参考文献 28

[1]	Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [J].The Lancet, 2020, 395(10224): 565-574.
[2]	Jiang S, Shi Z, Shu Y, et al. A distinct name is needed for the new coronavirus [J]. The Lancet, 2020, 395(10228): 949.
[3]	Wu Y, Ho W, Huang Y, et al. SARS-CoV-2 is an appropriate name for the new coronavirus [J]. The Lancet, 2020, 395(10228): 949-950.
[4]	Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2 [J]. Natl Sci Rev, 2020, 10(10): 1-12.
[5]	刘奇, 夏帅, 姜世勃. 抗新型冠状病毒2019-nCoV新药的研发 [J]. 中国临床药理学与治疗学, 2020, 25(3): 241-245.
[6]	Han DP, Penn-Nicholson A, Cho MW. Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor [J]. Virol, 2006, 350(1): 15-25.
[7]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor [J]. Cell, 2020, 182(2): 271-280.
[8]	Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus [J]. Proc Natl Acad Sci U S A, 2004,101(44): 15748-15753.
[9]	Shirato K, Kawase M, Matsuyama S. Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2 [J]. J Virol, 2013, 87(23): 12552-12561.
[10]	Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry [J]. Antiviral Res, 2016, 116: 76-84.
[11]	Hatesuer B, Bertram S, Mehnert N, et al. Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice [J]. Plos Pathogens, 2013, 9(12): e1003774.
[12]	Jorquera PA, Mathew C, Pickens JA, et al. Verdinexor (KPT-335), a selective inhibitor of nuclear export, reduces respiratory syncytial virus replication in vitro [J]. J Virol, 2018, 93(4): 1-17.
[13]	Rossignol JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent [J]. Antiviral Res, 2014, 110: 94-103.
[14]	Javier Carbajo-Lozoya, Yue Ma-Lauer, Miroslav Maleevi, et al.Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir [J]. Virus Res, 2014, 184: 44-53.
[15]	Dyall J, Coleman CM, Hart BJ, et al.Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection [J]. Antimicrob Agents Chemother, 2014, 58(8): 4885-4893.
[16]	Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the united states [J]. N Engl J Med, 2020. Doi:10.1056/NEJMoa2001191.
[17]	Cohen J. Can an anti-HIV combination or other existing drugs outwit the new coronavirus [J/OL]? Science,2020.https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus.
[18]	蓝巧帅, 夏帅, 周洁, 等. 新型冠状病毒SARS-CoV-2感染治疗中的"老药新用" [J]. 中国临床药理学与治疗学, 2020, 25(2): 126-134.
[19]	Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [J]. Cell Res, 2020, 30(10223): 269-271.
[20]	Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [J]. The Lancet, 2020, 395(10223):e30-e31.
[21]	Zumla A, Chan JF, Azhar EI, et al. Coronaviruses - drug discovery and therapeutic options [J]. Nat Rev Drug Discov, 2016, 15(5): 327-347.
[22]	Guangdi Li, Erik De Clercq. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) [J]. Nat rev Drug Discov, 2020,19(3): 149-150.
[23]	Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays [J]. J General Viro, 2014, 95: 571-577.
[24]	Al-Tawfiq JA, Momattin H, Dib J, et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study [J]. Int J Infect Dis, 2014, 20: 42-46.
[25]	Nukoolkarn V, Lee VS, Malaisree M, et al. Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors [J]. J Theo Biolog, 2008, 254(4): 861-867.
[26]	Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds [J]. J Clin Virol, 2004, 31(1): 69-75.
[27]	Weng JR, Lin CS, Lai HC, et al. Antiviral activity of sambucus formosananakai ethanol extract and related phenolic acid constituents against human coronavirus NL63 [J]. Virus Res, 2019, 273: 197767.
[28]	观察者网. 中科院发现30种药物可能对新型冠状病毒有效[N]. 观察者网, 2020.https://www.guancha.cn/politics/2020_01_25_533108.shtml?s=zwytt.

抗新型冠状病毒药物与治疗浅谈

Therapeutic drugs and treatment of SARS-CoV-2

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[2]	戴加惠, 孙思嘉, 解雪峰. 医疗器械临床试验质量管理及指标体系研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 51-58.
[3]	陈建芳, 娄冬华. 基于CDASH标准的肿瘤临床试验病例报告表设计[J]. 中国临床药理学与治疗学, 2022, 27(7): 762-767.
[4]	刘星, 卢晓然, 吴影, 于海涛, 王晓敏. 人工智能应用于临床试验的伦理问题分析及对策[J]. 中国临床药理学与治疗学, 2022, 27(3): 322-327.
[5]	朱丽丽, 朱秀秀, 王文俊, 张海邻, 林立. 国内儿科人群吸入制剂药物临床试验现状分析[J]. 中国临床药理学与治疗学, 2022, 27(2): 178-183.
[6]	李珊珊, 顾静文, 张菁, 杨海静, 刘薇, 喻一奇, 张文宏. 新冠病毒疫苗与单克隆中和抗体各期临床试验设计及评价概述[J]. 中国临床药理学与治疗学, 2022, 27(2): 190-197.
[7]	邓锟红, 刘亚昕, 孙媛媛, 陈文静, 杨楠, 胡展晴, 陈凯锋, 黄洁, 项玉霞, 阳国平. 2009－2020年药物首次人体试验设计及结果文献分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 77-85.
[8]	郑莹, 张玲, 姚丽, 王乾合, 朱克祥. 聚腺苷二磷酸-核糖聚合酶抑制剂在胰腺癌中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(1): 108-115.
[9]	佘志华, 陈舟, 梁松岳. 基于云架构的药物临床试验伦理审查信息化体系建设[J]. 中国临床药理学与治疗学, 2021, 26(9): 1023-1030.
[10]	宋岩, 高琳艳, 张艳平, 李想, 张兰. 医疗失效模式与效应分析在I期临床试验血液样本管理中的应用[J]. 中国临床药理学与治疗学, 2021, 26(9): 1031-1036.
[11]	彭静, 宋静, 栾家杰. 新型冠状病毒肺炎治疗新策略：间充质干细胞疗法[J]. 中国临床药理学与治疗学, 2021, 26(9): 1073-1079.
[12]	郝海平. 我国代谢调控与药物靶标发现研究的进展与展望[J]. 中国临床药理学与治疗学, 2021, 26(8): 955-963.
[13]	欧阳晨溪, 黄洁, 项玉霞, 王晓敏. 早期临床试验的伦理问题及对策探讨[J]. 中国临床药理学与治疗学, 2021, 26(7): 802-807.
[14]	黄丽红, 王陵, 言方荣, 魏朝晖, 赵杨, 夏结来, 陈峰. 新视角解读临床试验中的意向性原则[J]. 中国临床药理学与治疗学, 2021, 26(4): 449-453.
[15]	张茜, 胡伟, 余斌, 秦慧玲, 陈明壮, 鲁超. 基于文献分析法的药物临床试验信息化建设[J]. 中国临床药理学与治疗学, 2021, 26(2): 182-189.